Clinical Trials at Retina Northwest

Retina Northwest is committed to fostering cutting edge treatments for retinal diseases through our participation in clinical trials. Brief descriptions of our active clinical trials are listed below.  If you are a physician and have questions about any of our trials, or if you would like to refer a patient to our care, please contact our Clinical Research department at 503-274-2121.

Age-Related Macular Degeneration (AMD)

Atrophic (“Dry”)

GALA

822310 (Dry AMD)
Principal Investigator: Apurva Patel MD
Study Coordinator: Marcia Kopfer
Active, Enrollment Closed

Evaluation of alpha lipoic acid as a potential treatment for Geographic Atrophy in subjects with Age-Related Macular Degeneration.

OPH2003

OPH2003 (Dry AMD)
Principal Investigator: Apurva Patel MD
Study Coordinator: Pua Smith
Pending, Enrolling in December 2017

A phase 2b randomized, double-masked, controlled trial to assess the efficacy of intravitreous administration of Zimura (Anti-C5 Aptamer) in subjects with Geographic Atrophy secondary to Dry Age-Related Macular Degeneration.

OLEi

GX28198 (Dry AMD)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett
Not Active, Enrollment Closed

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab (FCFD4574S) in patients with Geographic Atrophy who have completed Genentech-Sponsored Lamalizumab studies.

Omaspect

GX30191 (Dry AMD)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett
Not Active, Enrollment Closed

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration who have completed a Roche-Sponsored study.

Spectri

GX29185 (Dry AMD)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett
Not Active, Enrollment Closed

A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravireally to patients with Geographic Atrophy secondary to Age-Related Macular Degeneration.

 

Exudative (“Wet”)

Ladder

GX28228 (Wet AMD)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett
Active, Enrollment Closed

A phase II multicenter, randomized, active treatment-controlled study of the efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with Subfoveal Neovascular Age-Related Macular Degeneration.

Sub-Study Ladder OAT

GX28228
Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett
Active, Currently Enrolling

Oral antithrombotic therapy sub-study associated with study GX28228. A phase II, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with Subfoveal Neovascular Age-Related Macular Degeneration.

ONYX

R910-3-AMD-1517 (Wet AMD)
Principal Investigator: Michael Lee MD
Study Coordinator: Marcia Kopfer
Not Active, Enrollment Closed

A randomized, double-masked, active-controlled phase 2 study of the efficacy, safety and tolerability of repeated doses of intravitreal REGN910-3 in patients with Neovascular Age-Related Macular Degeneration.

OPH2007

OPH2007 (Wet AMD)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Pua Smith
Active, Currently Enrolling

A phase 2A open-label trial to assess the safety of Zimura (Anti-C5) administered in combination with Lucentis 0.5mg in treatment naive subjects with Neovascular Age-Related Macular Degeneration.

Stairway

CR39521 (Wet AMD)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Marcia Kopfer
Active, Enrollment Closed

Simultaneous blockade of angiopoetin-2 and VEGF-A with the bi-specific antibody R06867461 (RG7716) for extended durability in the treatment of Neovascular Age-Related Macular Degeneration.

Alcon Hawk

Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett

Not Active, Enrollment Closed

A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus Aflibercept in subjects with Neovascular Age-Related Macular Degeneration.

Diabetic Eye Diseases

Diabetic Retinopathy

Boulevard Diabetic Retinopathy

BP30099 (DME)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett
Active, Enrollment Closed

A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28 week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with Diabetic Macular Edema.

DRCR Series of Studies

Principal Investigator: Apurva Patel MD
Study Coordinator: Pua Smith
Active, Currently Enrolling

Randomized Trial of Intravitreous Aflibercept vs. Intravitreous Bevacizumab plus Aflibercept for Treatment for Central-Involved Diabetic Macular Edema.

DRCR Series of Studies

Principal Investigator: Mark Peters, MD
Study Coordinator: Pua Smith
Active, Enrollment Closed

A Comparative Effectiveness Study of Intravitrela Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema Extension Study

DRCR Series of Studies

Principal Investigator: Mark Peters MD
Study Coordinator: Pua Smith
Active, Enrollment Closed

Treatment for CI-DME with VA Study.

DRCR Series of Studies

Principal Investigator: Mark Peters, MD
Study Coordinator: Pua Smith
Active, Currently Enrolling

Intravitreous Anti-VEGF treatment for prevention of Vision Threatening Diabetic Retinopathy in eyes at high risk.

Vein Occlusions

SCORE LTF

SCORE LTF (Vein Occlusion)
Principal Investigator: Mark Peters MD
Study Coordinator: Marcia Kopfer
Active, Enrollment Closed

Study of comparative treatments for Retinal Vein Occlusion 2: A multicenter, prospective, randomized non-inferiority trial of eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, comparing intravitreal Bevacizumab every 4 weeks with intravitreal Aflibercept every 4 weeks.

Macular Telangiectasia

Macular Telangiectasia Registry

Principal Investigator: Michael Lee, MD
Study Coordinator: Pua Smith
Active, Currently Enrolling

A natural history observation and registry study of Macular Telangiectasia Type 2: The MacTel Study

Neurotech Macular Telangiecasia Surgical Study Phase 3

Principal Investigator: Michael Lee, MD
Study Coordinator: Brian Puckett
Active, Currently Enrolling

A phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus in Macular Telangiectasia Type 2.

A A A